Edition:
United States

VIVUS Inc (VVUS.OQ)

VVUS.OQ on NASDAQ Stock Exchange Global Select Market

1.01USD
18 Aug 2017
Change (% chg)

$0.01 (+1.00%)
Prev Close
$1.00
Open
$1.00
Day's High
$1.01
Day's Low
$0.98
Volume
242,812
Avg. Vol
112,304
52-wk High
$1.47
52-wk Low
$0.98

VVUS.OQ

Chart for VVUS.OQ

About

VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA... (more)

Overall

Beta: 0.89
Market Cap(Mil.): $106.87
Shares Outstanding(Mil.): 105.81
Dividend: --
Yield (%): --

Financials

  VVUS.OQ Industry Sector
P/E (TTM): 3.33 31.45 32.56
EPS (TTM): 0.30 -- --
ROI: 15.28 15.33 14.89
ROE: -- 16.35 16.13

Vivus, Teva settle lawsuit over Teva's planned generic Qsymia

Vivus Inc has reached an agreement allowing Teva Pharmaceuticals Ltd to launch a generic version of its anti-obesity drug Qsymia by December 2024, settling a patent lawsuit Vivus brought in New Jersey federal court.

Jul 06 2017

BRIEF-Vivus announces settlement with Actavis on Qsymia patent litigation

* Vivus announces settlement with actavis on qsymia(r) patent litigation

Jul 05 2017

BRIEF-Vivus reports Q1 loss per share $0.01

* Total revenue, net for first quarters of 2017 and 2016, was $27.0 million and $15.3 million, respectively

May 03 2017

BRIEF-Vivus reacquires Stendra(R)(AVANAFIL)commercial rights from Sanofi

* Reacquires Stendra(R) (Avanafil) commercial rights from Sanofi

Mar 27 2017

Competitors

Earnings vs. Estimates